Changes in sexual behavior among women in studies evaluating the dapivirine vaginal ring for HIV prevention
Kudzai Hlahla, Moni Neradilek, Morgan Garcia, Felix Mhlanga, Thesla Palanee-Phillips, Krishnaveni Reddy, Nishanta Singh, Carolyne A. Akello, Samantha Siva, Leila E. Mansoor, Cindy E. Jacobson, Brenda Gati, Jennifer E. BalkusBackground
Access to novel HIV prevention technologies often raise concerns of risk compensation. This analysis examined changes in the sexual behaviors of MTN 020/ASPIRE participants, a placebo controlled randomized control trial, who subsequently enrolled in MTN-025/HOPE, an open-label extension using the dapivirine vaginal ring.
Methods
Both studies enrolled healthy, sexually active, HIV-negative women from Malawi, South Africa, Uganda and Zimbabwe. Longitudinal data on participants’ sexual behaviors, specifically sex with a nonprimary partner (past 3 months), and use of male or female condoms at the last vaginal sex act were compared between ASPIRE and HOPE. Conditional and mixed ordinal logistic regression models evaluated associations between study and sexual behaviors at enrollment, and quarterly over the first 12 months.
Results
Of the 2629 individuals enrolled in ASPIRE, 1456 (55%) participated in HOPE. At enrollment, the proportion of participants who reported sex with a nonprimary partner and condom use at last vaginal sex act did not differ by study. Across all quarterly follow-up visits, sex with a nonprimary partner was more common in HOPE (13.9–18.7%) than ASPIRE (10.7–12.6%); adjusted OR 1.47, 95% CI 1.24–1.75, P < 0.001. There was no difference in condom use at the last vaginal act across all quarterly follow-up visits between ASPIRE (36.5–42.7%) and HOPE (43.6–46.7%); adjusted OR 1.05, 95% CI 0.94–1.18.
Conclusion
More women reported sex with nonprimary partners in HOPE, with little change in condom use over time between the two studies. Understanding behavior changes during PrEP use allows for tailored, holistic reproductive health programming.